Estrogen replacement reverses endothelial dysfunction in postmenopausal women

David E. Bush, Calvin E. Jones, Katherine Miller-Bass, Gerald K. Walters, John M. Bruza, Pamela Ouyang

Research output: Contribution to journalArticle

Abstract

PURPOSE: To measure the effect of long-term clinical hormone replacement therapy on brachial artery vasomotor responses, and to compare these responses in premenopausal and postmenopausal women. PATIENTS AND METHODS: We studied 23 postmenopausal women, including 18 who were evaluated prior to starting clinically indicated oral hormone replacement therapy. Twelve postmenopausal women received estrogen alone, the other 6 were treated with estrogen/medroxyprogesterone combinations. Eleven premenopausal volunteers served as a comparison group. Change in brachial artery diameter in response to postischemic hyperemic flow and sublingual nitroglycerin was measured by ultrasound. RESULTS: The 18 postmenopausal subjects receiving hormone replacement showed a progressive improvement in their postischemic vasodilation. Mean (±SD) postischemic vasodilation was 0.4% ± 7.1% prior to estrogen replacement. There were significant increases in postischemic vasodilation of 4.8% ± 6.6% after 1 month and 8.3% ± 3.4% after 6 months of estrogen replacement. The response to nitroglycerin was similar at all time points studied. Women with the most abnormal responses to hyperemic flow at baseline demonstrated the greatest improvement after 6 months of hormone replacement therapy. Premenopausal and postmenopausal subjects differed in their response to hyperemic flow, with premenopausal women showing 5.8% vasodilatation compared with a 0.6% vasodilation in postmenopausal women (P = 0.046). CONCLUSIONS: Endothelial function is abnormal in many postmenopausal women compared with premenopausal women, and in some postmenopausal women it can be enhanced by estrogen replacement therapy. This effect may increase with prolonged use.

Original languageEnglish (US)
Pages (from-to)552-558
Number of pages7
JournalAmerican Journal of Medicine
Volume104
Issue number6
DOIs
StatePublished - Jun 1998

Fingerprint

Estrogen Replacement Therapy
Vasodilation
Hormone Replacement Therapy
Brachial Artery
Nitroglycerin
Estrogens
Medroxyprogesterone
Volunteers
Hormones

ASJC Scopus subject areas

  • Nursing(all)

Cite this

Estrogen replacement reverses endothelial dysfunction in postmenopausal women. / Bush, David E.; Jones, Calvin E.; Miller-Bass, Katherine; Walters, Gerald K.; Bruza, John M.; Ouyang, Pamela.

In: American Journal of Medicine, Vol. 104, No. 6, 06.1998, p. 552-558.

Research output: Contribution to journalArticle

@article{0dae806a00a541bd9877a0f56fa09149,
title = "Estrogen replacement reverses endothelial dysfunction in postmenopausal women",
abstract = "PURPOSE: To measure the effect of long-term clinical hormone replacement therapy on brachial artery vasomotor responses, and to compare these responses in premenopausal and postmenopausal women. PATIENTS AND METHODS: We studied 23 postmenopausal women, including 18 who were evaluated prior to starting clinically indicated oral hormone replacement therapy. Twelve postmenopausal women received estrogen alone, the other 6 were treated with estrogen/medroxyprogesterone combinations. Eleven premenopausal volunteers served as a comparison group. Change in brachial artery diameter in response to postischemic hyperemic flow and sublingual nitroglycerin was measured by ultrasound. RESULTS: The 18 postmenopausal subjects receiving hormone replacement showed a progressive improvement in their postischemic vasodilation. Mean (±SD) postischemic vasodilation was 0.4{\%} ± 7.1{\%} prior to estrogen replacement. There were significant increases in postischemic vasodilation of 4.8{\%} ± 6.6{\%} after 1 month and 8.3{\%} ± 3.4{\%} after 6 months of estrogen replacement. The response to nitroglycerin was similar at all time points studied. Women with the most abnormal responses to hyperemic flow at baseline demonstrated the greatest improvement after 6 months of hormone replacement therapy. Premenopausal and postmenopausal subjects differed in their response to hyperemic flow, with premenopausal women showing 5.8{\%} vasodilatation compared with a 0.6{\%} vasodilation in postmenopausal women (P = 0.046). CONCLUSIONS: Endothelial function is abnormal in many postmenopausal women compared with premenopausal women, and in some postmenopausal women it can be enhanced by estrogen replacement therapy. This effect may increase with prolonged use.",
author = "Bush, {David E.} and Jones, {Calvin E.} and Katherine Miller-Bass and Walters, {Gerald K.} and Bruza, {John M.} and Pamela Ouyang",
year = "1998",
month = "6",
doi = "10.1016/S0002-9343(98)00117-X",
language = "English (US)",
volume = "104",
pages = "552--558",
journal = "American Journal of Medicine",
issn = "0002-9343",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Estrogen replacement reverses endothelial dysfunction in postmenopausal women

AU - Bush, David E.

AU - Jones, Calvin E.

AU - Miller-Bass, Katherine

AU - Walters, Gerald K.

AU - Bruza, John M.

AU - Ouyang, Pamela

PY - 1998/6

Y1 - 1998/6

N2 - PURPOSE: To measure the effect of long-term clinical hormone replacement therapy on brachial artery vasomotor responses, and to compare these responses in premenopausal and postmenopausal women. PATIENTS AND METHODS: We studied 23 postmenopausal women, including 18 who were evaluated prior to starting clinically indicated oral hormone replacement therapy. Twelve postmenopausal women received estrogen alone, the other 6 were treated with estrogen/medroxyprogesterone combinations. Eleven premenopausal volunteers served as a comparison group. Change in brachial artery diameter in response to postischemic hyperemic flow and sublingual nitroglycerin was measured by ultrasound. RESULTS: The 18 postmenopausal subjects receiving hormone replacement showed a progressive improvement in their postischemic vasodilation. Mean (±SD) postischemic vasodilation was 0.4% ± 7.1% prior to estrogen replacement. There were significant increases in postischemic vasodilation of 4.8% ± 6.6% after 1 month and 8.3% ± 3.4% after 6 months of estrogen replacement. The response to nitroglycerin was similar at all time points studied. Women with the most abnormal responses to hyperemic flow at baseline demonstrated the greatest improvement after 6 months of hormone replacement therapy. Premenopausal and postmenopausal subjects differed in their response to hyperemic flow, with premenopausal women showing 5.8% vasodilatation compared with a 0.6% vasodilation in postmenopausal women (P = 0.046). CONCLUSIONS: Endothelial function is abnormal in many postmenopausal women compared with premenopausal women, and in some postmenopausal women it can be enhanced by estrogen replacement therapy. This effect may increase with prolonged use.

AB - PURPOSE: To measure the effect of long-term clinical hormone replacement therapy on brachial artery vasomotor responses, and to compare these responses in premenopausal and postmenopausal women. PATIENTS AND METHODS: We studied 23 postmenopausal women, including 18 who were evaluated prior to starting clinically indicated oral hormone replacement therapy. Twelve postmenopausal women received estrogen alone, the other 6 were treated with estrogen/medroxyprogesterone combinations. Eleven premenopausal volunteers served as a comparison group. Change in brachial artery diameter in response to postischemic hyperemic flow and sublingual nitroglycerin was measured by ultrasound. RESULTS: The 18 postmenopausal subjects receiving hormone replacement showed a progressive improvement in their postischemic vasodilation. Mean (±SD) postischemic vasodilation was 0.4% ± 7.1% prior to estrogen replacement. There were significant increases in postischemic vasodilation of 4.8% ± 6.6% after 1 month and 8.3% ± 3.4% after 6 months of estrogen replacement. The response to nitroglycerin was similar at all time points studied. Women with the most abnormal responses to hyperemic flow at baseline demonstrated the greatest improvement after 6 months of hormone replacement therapy. Premenopausal and postmenopausal subjects differed in their response to hyperemic flow, with premenopausal women showing 5.8% vasodilatation compared with a 0.6% vasodilation in postmenopausal women (P = 0.046). CONCLUSIONS: Endothelial function is abnormal in many postmenopausal women compared with premenopausal women, and in some postmenopausal women it can be enhanced by estrogen replacement therapy. This effect may increase with prolonged use.

UR - http://www.scopus.com/inward/record.url?scp=0032104352&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032104352&partnerID=8YFLogxK

U2 - 10.1016/S0002-9343(98)00117-X

DO - 10.1016/S0002-9343(98)00117-X

M3 - Article

C2 - 9674718

AN - SCOPUS:0032104352

VL - 104

SP - 552

EP - 558

JO - American Journal of Medicine

JF - American Journal of Medicine

SN - 0002-9343

IS - 6

ER -